IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0254252
(2005-10-18)
|
등록번호 |
US-7439042
(2008-10-21)
|
발명자
/ 주소 |
- Duke,Richard C.
- Franzusoff,Alex
- Haller,Aurelia
- King,Thomas H.
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
35 인용 특허 :
28 |
초록
▼
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in co
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.
대표청구항
▼
What is claimed is: 1. An HCV Core-E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist essentially of an HCV fusion protein comprising a full-length HCV Core protein fused to a full-length HCV E1 protein fused to a full-length HCV E2 protein, wherein the full-length HCV
What is claimed is: 1. An HCV Core-E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist essentially of an HCV fusion protein comprising a full-length HCV Core protein fused to a full-length HCV E1 protein fused to a full-length HCV E2 protein, wherein the full-length HCV Core protein is linked at its N-terminus to the amino acid sequence represented by SEQ ID NO:9 (MADEAP). 2. The fusion protein of claim 1, wherein the fusion protein consists essentially of SEQ ID NO:12. 3. The fusion protein of claim 1, wherein the HCV fusion protein has been appended to include two amino acids, glutamate and aspartate. 4. The fusion protein of claim 1, wherein the HCV fusion protein has been appended to include the amino acid sequence of G-G-G-H-H-H-H-H-H (SEQ ID NO:10). 5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the HCV Core-E1-E2 fusion protein of claim 1. 6. The isolated nucleic acid molecule of claim 5, wherein the expression of the fusion protein is under the control of an inducible promoter. 7. The isolated nucleic acid molecule of claim 6, wherein the inducible promoter is CUP1. 8. A recombinant nucleic acid molecule comprising the isolated nucleic acid molecule of claim 5. 9. A recombinant cell that has been transfected with the recombinant nucleic acid molecule of claim 8. 10. The recombinant cell of claim 9, wherein the cell is a yeast cell. 11. A composition comprising the nucleic acid molecule of claim 5. 12. A composition comprising the HCV Core-E1-E2 fusion protein of claim 1. 13. A composition comprising: a) a yeast vehicle; and b) the HCV Core-E1-E2 fusion protein of claim 1. 14. The composition of claim 13, wherein the HCV Core-E1-E2 fusion protein consists essentially of SEQ ID NO:14. 15. The composition of claim 13, wherein the expression of the fusion protein is under the control of an inducible promoter. 16. The composition of claim 13, wherein the composition further comprises a dendritic cell, wherein the dendritic cell has been loaded intracellularly with the yeast vehicle that recombinantly expresses the HCV Core-E1-E2 fusion protein. 17. The composition of claim 13, further comprising at least one biological response modifier. 18. A composition comprising: a) a yeast vehicle; and b) an HCV Core-E1-E2 fusion protein according to claim 2, wherein the HCV Core-E1-E2 fusion protein is under the control of the promoter CUP1; wherein the HCV Core-E1-E2 fusion protein is expressed by the yeast vehicle. 19. An HCV Core-E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist essentially of a truncated HCV Core protein fused to an HCV E1 protein with deleted transmembrane domain and an HCV E2 protein with deleted transmembrane domain, wherein the truncated HCV Core protein is linked at its N-terminus to the amino acid sequence represented by SEQ ID NO:9 (MADEAP). 20. The fusion protein of claim 19, wherein the truncated HCV Core protein consists essentially of positions 2 to 140 of HCV Core protein (positions 2 to 140, with respect to SEQ ID NO:20). 21. The fusion protein of claim 19, wherein the HCV E1 protein with deleted transmembrane domain consists essentially of positions 1 to 156 of HCV E1 protein (positions 192 to 31, with respect to SEQ ID NO:20). 22. The fusion protein of claim 19, wherein the HCV E2 protein with deleted transmembrane domain consists essentially of positions 1 to 334 of HCV E2 protein (positions 384 to 717, with respect to SEQ ID NO:20). 23. The fusion protein of claim 19, wherein the fusion protein consists essentially of SEQ ID NO:14. 24. A composition comprising: a) a yeast vehicle; and b) an HCV Core-E1-E2 fusion protein according to claim 23, wherein the HCV Core-E1-E2 fusion protein is under the control of the promoter CUP1; wherein the HCV Core-E1-E2 fusion protein is expressed by the yeast vehicle. 25. A composition comprising: a) a yeast vehicle; and b) the HCV Core-E1-E2 fusion protein of claim 19. 26. The composition of claim 25, wherein the fusion protein consists essentially of SEQ ID NO:14. 27. An HCV E1-E2 fusion protein comprising HCV sequences, wherein the HCV sequences consist of a an HCV E1 protein fused to an HCV E2 protein, wherein the HCV E1 protein is linked at its N-terminus to the amino acid sequence represented by SEQ ID NO:9 (MADEAP). 28. The HCV E1-E2 fusion protein of claim 27, wherein the fusion protein consists essentially of SEQ ID NO:6. 29. The fusion protein of claim 27, wherein the HCV fusion protein has been appended to include two amino acids, glutamate and aspartate. 30. The fusion protein of claim 27, wherein the HCV fusion protein has been appended to include the amino acid sequence of G-G-G-H-H-H-H-H-H (SEQ ID NO:10). 31. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the HCV E1-E2 fusion protein of claim 27. 32. The isolated nucleic acid molecule of claim 31, wherein the nucleic acid sequence is SEQ ID NO:5. 33. The isolated nucleic acid molecule of claim 31, wherein the expression of the fusion protein is under the control of an inducible promoter. 34. The isolated nucleic acid molecule of claim 32, wherein the inducible promoter is CUP1. 35. A recombinant nucleic acid molecule comprising the isolated nucleic acid molecule of claim 27. 36. A recombinant cell that has been transfected with the recombinant nucleic acid molecule of claim 35. 37. The recombinant cell of claim 36, wherein the cell is a yeast cell. 38. A composition comprising the HCV E1-E2 fusion protein of claim 27. 39. A composition comprising: a) a yeast vehicle; and b) the HCV E1-E2 fusion protein of claim 27. 40. The composition of claim 39, wherein the HCV E1-E2 fusion protein consists essentially of SEQ ID NO:6. 41. A composition comprising: a) a yeast vehicle; and b) an HCV E1-E2 fusion protein according to claim 28, wherein the HCV E1-E2 fusion protein is under the control of the promoter CUP1; wherein the HCV E1-E2 fusion protein is expressed by the yeast vehicle. 42. The composition of claim 41, wherein the HCV E1-E2 fusion protein has been appended to include the amino acid sequence of G-G-G-H-H-H-H-H-H (SEQ ID NO:10).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.